Cannabis and Endometriosis: Can It Relieve Chronic Pelvic Pain?

Endometriosis is a chronic inflammatory condition in which tissue similar to the uterine lining grows outside the uterus, causing pain, scarring, and sometimes infertility. It affects an estimated 1 in 10 women of reproductive age and is one of the leading causes of chronic pelvic pain worldwide.

Standard treatments — including hormonal therapy, NSAIDs, and surgery — often fail to fully relieve pain or come with significant side effects. As a result, more patients are exploring medical cannabis for endometriosis as an alternative or complementary approach. Cannabinoids such as CBD and THC are known to influence pain signaling, inflammation, and muscle tone, raising the question: could cannabis help manage endometriosis-related pelvic pain when conventional options fall short?

This article explores how endometriosis causes pain, the role of the endocannabinoid system (ECS) in reproductive health, and what current research says about using cannabinoids to improve quality of life for people living with this condition.

Pathophysiology of Endometriosis: Why It Hurts So Much

Endometriosis pain is driven by a combination of chronic inflammation, nerve growth, and central pain sensitization. These mechanisms make the pain persistent, severe, and often resistant to standard treatments.

Chronic Inflammation

• Endometriotic lesions produce high levels of pro-inflammatory cytokines such as IL-6, TNF-α, and IL-1β.
• These mediators promote swelling, local tissue damage, and heightened pain sensitivity.
• Persistent inflammation also contributes to fatigue and systemic symptoms beyond the pelvis.

Nerve Growth and Sensitization

• Lesions can stimulate neuroangiogenesis — the growth of new nerve fibers and blood vessels inside the abnormal tissue.
• This creates a direct physical pathway for pain signaling from the lesions to the spinal cord.
• Sensory nerves in these areas show lower activation thresholds, sending stronger pain signals from minimal stimuli.

Central Sensitization

• Over time, constant pain input rewires the central nervous system, a process called central sensitization.
• The brain and spinal cord become hyperresponsive to pain, amplifying even minor sensations.
• This explains why endometriosis pain often persists even after surgical removal of lesions.

Because multiple biological pathways sustain the pain, effective management likely requires treatments that address inflammation, nerve excitability, and central pain processing simultaneously — which is why cannabinoids have drawn increasing interest.

The Endocannabinoid System in Female Reproductive Tissues

The endocannabinoid system (ECS) is a key neuromodulatory network involved in regulating pain, inflammation, and reproductive function — making it highly relevant to endometriosis. Understanding how it operates in female reproductive tissues helps explain why cannabinoids like CBD and THC are being explored as potential therapies.

ECS Components in the Reproductive Tract

• CB1 receptors are found in the endometrium, myometrium, ovaries, and pelvic nerves, where they regulate pain signaling and smooth muscle contractility.
• CB2 receptors are expressed in immune cells within endometrial tissue and help modulate inflammatory responses.
• The body’s own cannabinoids, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), fluctuate across the menstrual cycle and influence implantation, menstruation, and uterine function.

ECS Dysregulation in Endometriosis

• Studies show reduced CB1 receptor expression in endometriotic lesions compared to healthy endometrium.
• Lower CB1 activity may impair the body’s ability to suppress pain signals, while reduced endocannabinoid tone contributes to heightened inflammation.
• Elevated levels of the enzyme FAAH, which breaks down anandamide, have been found in some patients, potentially limiting natural pain control.

Why This Matters

• Because the ECS is involved in both pain modulation and inflammatory control, restoring its balance through cannabinoids could target multiple drivers of endometriosis pain.
• This mechanistic link is the foundation for growing interest in medical cannabis for endometriosis, especially in patients who do not respond to standard pain therapies.

What the Research Says

Scientific evidence on cannabis for endometriosis is still limited but rapidly expanding. Most data come from preclinical studies, patient surveys, and small observational trials - with early findings suggesting that cannabinoids may reduce inflammation, suppress lesion growth, and relieve chronic pelvic pain.

Preclinical Evidence

Gupta et al., 2016 (Biology of Reproduction)

• Demonstrated that CB1 and CB2 receptor activation suppressed neuroangiogenesis (nerve and blood vessel growth) in endometrial-like lesions in mice.
• Lesion size was reduced by about 30–40% compared to controls.

Leconte et al., 2011 (Fertil Steril)

• Found that anandamide reduced COX-2 and NF-κB activity, two key pro-inflammatory pathways, in human endometrial cell cultures.
• Resulted in a 50% decrease in prostaglandin production, which drives uterine cramping and pain.

Resuehr et al., 2012 (Mol Hum Reprod)

• Reported that blocking FAAH (which breaks down anandamide) reduced pain-like behaviors in a rodent model of endometriosis, suggesting that enhancing endogenous ECS tone could relieve pain.

These studies support the idea that cannabinoids may act on multiple pain mechanisms - nerve growth, inflammation, and sensory sensitization.

Human Studies and Patient Surveys

Sinclair et al., 2019 (Journal of Obstetrics and Gynaecology Canada)

Surveyed 240 people with endometriosis:

• 59% reported using cannabis to manage symptoms.
• Among users, 95% reported pain reduction, and 50% reduced or stopped opioid use.

Armour et al., 2021 (PLOS One)

Online survey of 213 participants:

• Cannabis use was associated with a ~7.6/10 average pain reduction and improved sleep in 81% of users.
• Participants using inhaled or oral cannabis also reported less gastrointestinal pain and nausea.

Schueler et al., 2021 (Pain Med)

Pilot observational study of 37 women with endometriosis who used a CBD-dominant oil (20–50 mg/day).

After 8 weeks: average pelvic pain scores fell by 30%, and quality-of-life scores improved significantly.

Although these studies are small and self-reported, they consistently suggest clinically meaningful reductions in pain and improved daily functioning with cannabis use.

Ongoing and Planned Research

• NCT05441604 – A randomized controlled trial testing a CBD/THC oromucosal spray for chronic pelvic pain, including endometriosis-related pain (results expected 2025).
• NCT05268258 – Studying the effect of CBD capsules on inflammatory biomarkers and pain in endometriosis patients.
• Preclinical translational studies – Focused on mapping ECS activity in endometriotic lesions to identify biomarkers for cannabinoid responsiveness.

Key takeaway: While robust clinical trials are still lacking, both preclinical and early human data support the hypothesis that cannabinoids can reduce pain and inflammation in endometriosis, making them a promising target for future therapies.

Potential Benefits of Cannabinoids in Endometriosis

Although evidence is still emerging, current findings and mechanistic data suggest several ways cannabinoids could help manage endometriosis-related pain and improve quality of life.

Pain Relief Through Central and Peripheral Mechanisms

• CB1 receptor activation in the spinal cord and brain may reduce the transmission of pain signals from pelvic nerves.
• CB2 receptor activation on immune cells can decrease the release of pro-inflammatory cytokines, reducing peripheral sensitization.
• This dual action could target both local lesion pain and central pain amplification.

Anti-Inflammatory Effects

• CBD and THC can downregulate NF-κB and COX-2, key drivers of chronic inflammation in endometriosis lesions.
• Reduced inflammation may help shrink lesion activity and lower associated pain over time.

Muscle Relaxation and Cramp Reduction

• Cannabinoids can relax uterine and pelvic smooth muscle, which may relieve the intense cramping often reported during menstruation.

Improved Sleep and Mood

• Chronic pelvic pain often disrupts sleep and contributes to anxiety or depression.
• CBD may improve sleep continuity and reduce anxiety, while low doses of THC can help with sleep onset, indirectly improving pain tolerance.

Potential to Reduce Reliance on Other Medications

• Several surveys show that patients using cannabis for endometriosis reduced or discontinued opioids and NSAIDs, which carry long-term side effect risks.
• Cannabinoids could serve as a safer adjunctive therapy for pain control.

Safety and Clinical Considerations

While cannabinoids show promise for managing endometriosis-related pain, their use requires caution. Evidence is still limited, and individual responses can vary widely.

Potential Risks and Side Effects

• THC-related effects: Cognitive impairment (attention, memory), dizziness, sedation, and in some cases anxiety or paranoia — especially at higher doses.
• Reproductive considerations: Limited data on long-term cannabis use in women of reproductive age; potential concerns regarding fertility or pregnancy warrant avoiding cannabis during conception attempts or pregnancy.
• Drug interactions: Both THC and CBD are metabolized by CYP450 enzymes, which can affect the metabolism of hormonal contraceptives, antidepressants, or pain medications.

Safety Strategies

• Prefer CBD-dominant products for daytime use to reduce anxiety and inflammation without psychoactive effects.
• If THC is used, apply low doses (1–2.5 mg) and monitor for cognitive or mood-related side effects.
• Use regulated products with verified cannabinoid content to ensure consistency and safety.

Clinical Integration

• Cannabis should be considered only as an adjunct to standard therapies, not a replacement.
• Dosing should be individualized under medical supervision, especially when combined with other medications.
• Tracking pain scores, sleep, and overall functioning helps evaluate benefit and detect side effects early.

Conclusion: A Promising but Unproven Option

Endometriosis is a complex, chronic condition where pain persists despite conventional therapies, driving many patients to explore alternative approaches. Emerging evidence suggests that cannabinoids - especially CBD and low-dose THC - may help reduce inflammation, modulate pain signaling, relax pelvic muscles, and improve sleep and overall quality of life.

However, the current data are limited, mostly observational, and highly variable. There are still no large randomized controlled trials confirming the safety, efficacy, or optimal dosing of cannabis specifically for endometriosis-related pain.

Until stronger clinical evidence becomes available, medical cannabis should be considered an experimental adjunct, used cautiously and under professional supervision. Future research must clarify which patients benefit most, how to balance THC and CBD, and how to minimize potential reproductive or cognitive risks.

If validated in rigorous studies, cannabinoids could offer a much-needed new option for managing chronic pelvic pain and improving the lives of people with endometriosis.